Spectral Medical closed the C$6.3 million second and final tranche of a C$14.0 million convertible note offering. The first tranche, C$7.7 million, closed October 30.

Pinnacle Island II LP and Paradigm Capital bought the second tranche notes. They pay the Canadian Overnight Repo Rate Average plus 800 basis points, semi-annually, in cash or in kind at the company's option, and mature November 1, 2031. Conversion is C$1.00 a unit, each unit one common share plus half a warrant struck at C$1.10. Paradigm took a C$157,500 cash commission, C$157,500 in notes and 315,000 compensation options.

The company is seeking FDA approval for Toraymyxin, a hemoperfusion cartridge that strips endotoxin from the blood of septic shock patients. It won Breakthrough Device designation in July 2022 and still has items to answer in an FDA deficiency letter. Its Endotoxin Activity Assay is already cleared and selects which patients get the therapy. Proceeds go to general corporate and working capital.

A 2031 maturity on an eight point spread is expensive money, and it is the right trade for a company whose next milestone is a written response rather than a trial readout.